Take a trial of UK to unlock this pageFind out more

Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value
Margin of Safety (beta)
Screens Passed 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Jul 2009 2010 2011 2012 2013 2014 TTM 2015E 2016E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividends
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p -4.2%

FINANCIAL BRIEF: For the six months ended 31 January 2015, Avacta Group Plc revenues decreased 11% to L725K. Net loss before extraordinary items increased from L293K to L1.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Administrative expenses increase of 84% to L2.1M (expense). more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
D-
D-
Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %
vs.
market
vs.
industry
Recent History
Latest interim period (ended 31st Jan '15) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Jul 2015
31st Jul 2016

Price Target: 0.017
(+18.21% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
3 brokers Broker Consensus Trend
Broker Recommendations for Avacta
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 0 1 1

Named Brokers and Analysts
Panmure Gordon Savvas Neophytou , Numis Securities Charles Weston , Edison Investment Research Francesco Gregori , Equity Development Lorenza Castellon , Hume Capital Timothy Freeborn ,

Profile Summary

Avacta Group plc is a provider of research reagents, consumables and equipment to the life sciences and animal care markets. The Company provides research, development, production and delivery of instrumentation and services for the biopharmaceutical drug development and clinical diagnostics markets using biophysical technology. It operates through three segments: Analytical, Animal Health and Life Sciences. The Analytical segment provides tools and contract services for early stage protein characterisation and analysis for biopharmaceutical drug developers. The Animal Health segment provides tools and contract services to assist diagnosis of conditions in animals to enable faster treatment for veterinarians. The Life Sciences segment provides reagents and arrays for diagnostics, drug and biomarker discovery in biotech research and development. Its subsidiaries include Avacta Limited, Avacta Analytical Limited, Oriental Fine Foods Limited, Avacta Health Limited and others.

Directors: Alastair Smith (CEO) , Timothy Sykes (CFO) , Craig Slater (COO) 50, Gwyn Humphreys (NEC) 67, Michael Albin (NED) 56, Trevor Nicholls (NED) 58, Alan Aubrey (NID) 53, Anthony Robards (NID) ,

No. of Employees: 71 No. of Shareholders: n/a


Last Annual July 31st, 2014
Last Interim January 31st, 2015
Incorporated April 29, 2003
Public Since September 8, 2003
Shares in Issue 4,979,149,550
Free Float 2.62bn (52.7%)
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index FTSE Intl-aim All Share ,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2015.


Should you buy AVCT

Access AVCT Analytics Now!

FREE TRIAL or TAKE THE TOUR
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis
Foliobuilder